Welcome to our dedicated page for Telix Pharmaceuticals SEC filings (Ticker: TLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Telix Pharmaceuticals's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Telix Pharmaceuticals's regulatory disclosures and financial reporting.
Telix Pharmaceuticals Ltd Group Chief Operating Officer Darren Joel Patti filed an initial ownership report showing existing equity interests in the company. The filing lists 25,558 Ordinary Shares held directly and 804 American Depositary Receipts, each convertible into one ordinary share according to the footnotes.
It also discloses derivative awards over ordinary shares, including Performance Share Appreciation Rights over 15,826 shares at $4.9500 per share and 27,448 shares at $6.9000, both with future expiration dates. Share Rights cover an additional 15,000, 12,541, and 15,000 underlying ordinary shares at a $0.0000 exercise price, with vesting and exercisability tied to continued service and future testing of results. The report records holdings only and does not show new market purchases or sales.
Telix Pharmaceuticals Ltd director Marie Elizabeth McDonald has filed an initial ownership report on Form 3. The filing shows an indirect holding of 3,719 Ordinary Shares held through Netwealth Investments Limited as custodian. This is a disclosure of existing holdings rather than a new share purchase or sale.
Telix Pharmaceuticals Ltd director Jann Elizabeth Skinner has filed an initial ownership report showing a significant indirect stake in the company. The Form 3 discloses indirect ownership of 595,000 Ordinary Shares held through Forellan Pty Limited, where Ms. Skinner is the sole director and shareholder. This filing records her existing position rather than new share purchases or sales.
Telix Pharmaceuticals Ltd managing director and Group CEO Christian Behrenbruch has filed an initial statement of holdings, detailing his equity and derivative interests in the company. He holds performance share appreciation rights over 93,114 ordinary shares at an exercise price of 4.9500 (Australian dollars) expiring on April 4, 2027, and further rights over 100,223 ordinary shares at 6.9000 expiring on December 31, 2027. These PSARs were granted in April 2022 and May 2023 and are already vested and exercisable.
Behrenbruch also holds share rights over 2,595 ordinary shares at a zero exercise price, expiring on March 31, 2028, which are likewise vested and exercisable. Indirectly, 20,675,000 ordinary shares are held through Elk River Holdings Pty Ltd, where he is the sole director and shareholder. In addition, he directly owns 400,000 American Depositary Receipts, each convertible into one ordinary share with no expiration date, and 254,006 ordinary shares held directly.
Telix Pharmaceuticals Limited has resubmitted a New Drug Application to the U.S. FDA for TLX101-Px (Pixclara), a PET imaging agent designed to help distinguish recurrent or progressive glioma from treatment-related brain changes in adult and pediatric patients.
The resubmission includes additional data and statistical analyses requested in a prior Complete Response Letter, alongside the original primary data set. TLX101-Px has Orphan Drug and Fast Track designations, reflecting its potential to address a significant unmet need, as there is currently no FDA-approved targeted amino acid PET agent for adult and pediatric brain cancer imaging in the U.S.
Telix Pharmaceuticals Limited reports strong 2025 growth but lower profitability. Revenue rose to US$803.8 million, a 56% increase from 2024, driven by its Precision Medicine business and the RLS Radiopharmacies acquisition. Operating profit was US$29.8 million, yet higher R&D, manufacturing scale-up, and finance costs led to a net loss after tax of US$7.1 million, versus a US$33.7 million profit a year earlier.
Adjusted EBITDA declined to US$39.5 million as Telix increased R&D spending to US$171.2 million and expanded manufacturing infrastructure in the U.S., Europe, Japan, and Australia. Cash and equivalents fell to US$141.9 million from US$440.0 million, reflecting acquisition payments and capital investment, while the company continued advancing late-stage therapeutic trials and global product launches.
Telix Pharmaceuticals Limited submitted a European Marketing Authorization Application for its product candidate TLX101-Px, which is designed for brain cancer imaging. The company reported this regulatory milestone to U.S. investors by furnishing on Form 6-K the related announcement it filed with the Australian Securities Exchange.
Telix Pharmaceuticals Limited filed a Form 6-K highlighting two key updates first released on the Australian Securities Exchange. The company reports that the Chinese National Medical Products Administration has accepted a New Drug Application for Illucix, marking an important regulatory step for this product in China. Telix also states that it achieved its FY 2025 guidance with US$804 million (A$1.2 billion) in revenue and is accelerating growth with the launch of Gozellix. Together, these disclosures point to strong recent commercial performance and progress in expanding the company’s product portfolio and geographic reach.
Telix Pharmaceuticals Limited submitted a foreign issuer report to the U.S. securities regulator to furnish investors with a copy of a presentation given at the JP Morgan Healthcare Conference 2026. The company states that it filed an announcement with the Australian Securities Exchange on January 12, 2026 titled “Telix JP Morgan Healthcare Conference 2026 Presentation,” and has attached this as an exhibit for U.S. investors. This filing is primarily administrative, making the same information available in the U.S. market that was released in Australia.